路透北京10月27日 - 中国“复星系”医药及疫苗巨头--复星医药600196.SS2196.HK周二公布，三季度净利9.5亿元人民币，同比增长15.2%；扣除非经常性损益的净利则同比减少8.3%，因上期利润基数高、汇兑损失同比增加等。
以下为公司财报要点：
三季度营收100.2亿元，同比增长1.4%，主要源于创新药品收入增长
前三季度营收304.6亿元，同比增长3.6%
前三季度创新药品收入同比增长15.5%，占制药业务收入的比重达35.4%
前三季度净利26.7亿元，同比增长5.7%
前三季度研发总投入52.5亿元，同比增长31.2%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.